WellStar Cancer Network 2016 Annual Report
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
12 Regional Lymph Nodes<br />
Removed for<br />
Resected Colon <strong>Cancer</strong><br />
Adjuvant Chemotherapy for<br />
Stage III Colon <strong>Cancer</strong><br />
100<br />
80<br />
60<br />
94%<br />
85%<br />
100<br />
80<br />
60<br />
93%<br />
90%<br />
40<br />
40<br />
20<br />
20<br />
0<br />
<strong>WellStar</strong><br />
Benchmark<br />
0<br />
<strong>WellStar</strong><br />
Benchmark<br />
Benchmark: CP3R Expected Performance<br />
Benchmark: CP3R Expected Performance<br />
The American College of Pathologists recommended that<br />
a minimum of 12 lymph nodes be examined to accurately<br />
identify AJCC stage III colon cancer.<br />
Source: National Quality Forum<br />
Evidence that chemotherapy reduces the risk of distant<br />
disease recurrence and death in persons with nodepositive<br />
(Stage III) colon cancer.<br />
Source: National Quality Forum<br />
100<br />
80<br />
60<br />
40<br />
90-Day Mortality Following<br />
Pancreatic <strong>Cancer</strong> Surgery<br />
In the modern era, a 2%,<br />
30-day mortality can be<br />
expected at high-volume<br />
centers, and can be as high<br />
as 7% for 90-day mortality<br />
outcomes.<br />
20<br />
0<br />
0%<br />
<strong>WellStar</strong><br />
7%<br />
Benchmark<br />
Benchmark: CP3R Expected Performance<br />
<strong>WellStar</strong> performed 314<br />
surgeries and 240 cases<br />
were presented at tumor<br />
conference.<br />
Sahir Shroff, M.D.<br />
Gastrointestinal Sub<br />
Committee Chair<br />
Nancy Page, RN<br />
Gastrointestinal <strong>Cancer</strong><br />
Nurse Navigator<br />
WELLSTAR CANCER NETWORK • <strong>2016</strong> ANNUAL REPORT • 17
Change language